Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells

Hassane M. Zarour, John M. Kirkwood, Lisa Salvucci Kierstead, Wolfgang Herr, Vladimir Brusic, Craig L. Slingluff, John Sidney, Alessandro Sette, Walter J. Storkus

Research output: Journal PublicationArticlepeer-review

142 Citations (Scopus)

Abstract

The human Melan-A/MART-1 gene encodes an HLA-A2-restricted peptide epitope recognized by melanoma-reactive CD8+ cytotoxic T lymphocytes. Here we report that this gene also encodes at least one HLA-DR4-presented peptide recognized by CD4+ T cells. The Melan-A/MART-151-73 peptide was able to induce the in vitro expansion of specific CD4+ T cells derived from normal DR4+ donors or from DR4+ patients with melanoma when pulsed onto autologous dendritic cells. CD4+ responder T cells specifically produced IFN-γ in response to, and also lysed, T2.DR4 cells pulsed with the Melan-A/MART-151-73 peptide and DR4+ melanoma target cells naturally expressing the Melan-A/MART-1 gene product. Interestingly, CD4+ T cell immunoreactivity against the Melan-A/ MART-151-73 peptide typically coexisted with a high frequency of anti-Melan-A/MART-127-35 reactive CD8+ T cells in freshly isolated blood harvested from HLA-A2+/DR4+ patients with melanoma. Taken together, these data support the use of this Melan-A/ MART-1 DR4-restricted melanoma epitope in future immunotherapeutic trials designed to generate, augment, and quantitate specific CD4+ T cell responses against melanoma in vivo.

Original languageEnglish
Pages (from-to)400-405
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume97
Issue number1
DOIs
Publication statusPublished - 4 Jan 2000
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells'. Together they form a unique fingerprint.

Cite this